BIOELECTRONICS COMPLETES CONTROLLED CROSSOVER TRIAL.
The clinical study participants had on average, experienced chronic plantar fasciitis symptoms for close to 2.5 years. The two participant groups received both four (4) weeks of active therapy and then four (4) weeks of placebo treatment or vice versa. The study results showed strong improvement on a week by week basis, statistically above baseline at 4 weeks, 9 weeks and 26 weeks, with 26 weeks showing the most improvement for both pain and disability. Improvement at 26 weeks was the study primary end point and is indicative of tissue remodeling and healing. No adverse effects were reported. The study was conducted at the University of British Columbia and led by Professor Jack Taunton, Division of Sports Medicine, Faculty of Medicine.
The American Podiatric Medical Association reports that heel pain is the most prevalent medical condition being treated in podiatric clinics. Treatment options are limited, and currently there are no simple, low cost effective treatments available for sufferers of plantar fasciitis. ActiPatch offers an excellent treatment alternative.
Other Clinical Research
BioElectronics is conducting a series of clinical research studies using its medical devices for musculoskeletal pain conditions including, osteoarthritis of the knee, acute nonspecific lower back pain, and postoperative recovery for 3rd molar extraction and hernia surgical repair. Details can be found at http://www.bielcorp.com/clinical-evidence/.
About BioElectronics Corporation
BioElectronics Corporation is a prover of biophysics and the maker of a family of disposable, drug-free, anti- inflammatory devices: ActiPatch Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx Devices for chronic and post- operative wound care; Allay Menstrual Pain Therapy; and HealFast Therapy for dogs, cats and horses.
For more information, visit www.bielcorp.com or call 940/262-3584.